Using novel enzyme compounds Oxidien develops superior treatments for
secondary hyperoxaluria to ultimately prevent kidney stone disease.
Download Oxidien’s Latest Non-confidential Deck
PROUD TO PARTNER WITH:
Secondary hyperoxaluria is a disease with significant unmet medical need. Patients demonstrate wide ranging severity, from manageable symptoms to severe and chronic complications.
There are two types of Secondary (2°) Hyperoxaluria : Idiopathic Hyperoxaluria (IH) and Enteric Hyperoxaluria (EH) 1, 2, 3 .
IH is the most common type, and mostly observed in individuals with calcium oxalate kidney stones1, 4, 5. EH is partly caused by an underlying gastrointestinal complication associated with a malabsorption of oxalate. In these patients, oxalate becomes more available for absorption 2 , which can cause severe kidney damage and can lead to end-stage renal failure.
Oxidien estimates that there are 200,000 – 250,000 patients with enteric hyperoxaluria in the U.S. alone and 4 – 5 million people that are hyperoxaluric stone formers in the general U.S. population. For more information on the unmet need and the market in the U.S. and worldwide.
Novel and Clinically Studied Enzyme
OX-1 is a novel enzyme to treat hyperoxaluria that was developed with the support of multiple National Institute of Health (NIH) Small Business Innovation Research (SBIR) Grants. It exhibits a broad pH-activity profile and a superior stability and activity in the stomach. OX-1 has demonstrated biological effect in healthy volunteers and is the first product to demonstrate meaningful effect in subjects with dietary induced hyperoxaluria at upper limit of normal.
With its clinically studied product and
cost-efficient and scaled manufacturing process, Oxidien is poised to generate meaningful data in enteric hyperoxaluria patients with an economically realistic approach for the benefit of patients
Helena Cowley, Co-founder and CEO